14 Jan 2020 Novartis announces new collaboration for patients
21 Jan 2020 Pharmaceutical companies give NHS Scotland £1 million a week to help fund new treatments
22 Jan 2020 Government launches Statutory Scheme consultation
28 Jan 2020 Immigration reforms must support UK life sciences
03 Feb 2020 ABPI response to proposed UK-EU trade negotiation approaches
05 Feb 2020 New toolkit for Welsh NHS and industry to work together for patients
06 Feb 2020 ABPI response to proposed UK-‘Rest of the World’ FTA negotiation approaches
19 Feb 2020 ABPI response to new UK immigration system
27 Feb 2020 ABPI response to the UK’s approach to EU negotiations
02 Mar 2020 ABPI response to UK negotiating objectives for US FTA
11 Mar 2020 Pharmaceutical industry response to Budget 2020
16 Mar 2020 ABPI update on the pharmaceutical industry's response to coronavirus
19 Mar 2020 Q4 2019 figures for Voluntary Scheme published
01 Apr 2020 Joint statement on COVID-19 testing and diagnostics
08 Apr 2020 ABPI responds to Government’s coronavirus testing ‘call to arms’
23 Apr 2020 Global manufacturing ‘fundamental’ for continued NHS medicine supply
12 May 2020 ABPI response to safer working guidance
21 May 2020 ABPI comment on NIHR framework for restarting paused research
22 May 2020 ABPI response to quarantine measures
28 May 2020 Temporary changes to publication of 2019 data on Disclosure UK in June 2020
04 Jun 2020 Public-private alliance to provide immunisation programs for 300 million children globally
18 Jun 2020 ABPI response to antibiotic development scheme
19 Jun 2020 ABPI consults on new-look Code of Practice
30 Jun 2020 Pharmaceutical industry invests £381 million in UK R&D collaborations - 2019 data on Disclosure UK
01 Jul 2020 ABPI response to Government R&D Roadmap
06 Jul 2020 Supercharging R&D investment critical to boosting British business
08 Jul 2020 ABPI response to Cumberlege Review
08 Jul 2020 Pharmaceutical industry response to Chancellor’s economic statement
09 Jul 2020 $1 billion antibiotics research fund launched by pharmaceutical companies
14 Jul 2020 William Harbage QC to step down as Chair of the PMCPA Appeal Board
20 Jul 2020 Positive results for the Oxford vaccine welcomed by ABPI
29 Jul 2020 ABPI response to Committee inquiry into COVID-19 and international trade
04 Aug 2020 Preparing for the end of Brexit transition: Our response to DHSC guidance
07 Aug 2020 Northern Ireland Protocol: Our response to additional guidance
07 Aug 2020 Northern Ireland Protocol: Our response to additional guidance
18 Aug 2020 ABPI response to new National Institute for Health Protection
01 Sep 2020 ABPI supports AMRC call to protect charity research
01 Sep 2020 ABPI response to MHRA guidance for the end of the transition period
11 Sep 2020 Pharmaceutical industry reaction to UK-Japan trade agreement
28 Sep 2020 COVID threat must inject urgency into trade talks, say UK & EU pharma bodies
28 Sep 2020 ABPI response to UK genomics strategy
29 Sep 2020 ABPI response to NHS Confederation reports: NHS Reset and Health inequalities
30 Sep 2020 Last-ditch attempt to secure ‘bare minimum’ deal on medicines, MPs told
07 Oct 2020 UK leading Europe in clinical trials, but strategy needed to restart non-COVID research
08 Oct 2020 New partnership to reduce disease burden in Northern Ireland - starting with Hepatitis C
13 Oct 2020 ABPI response to Government-secured Brexit freight capacity
14 Oct 2020 ABPI response to UK joining Project Orbis and Access Consortium
16 Oct 2020 ABPI response to human medicines regulations changes
16 Oct 2020 ABPI response to PM's Brexit comments
20 Oct 2020 Northern Ireland life sciences sector ‘flourishing’
06 Nov 2020 ABPI response to consultation on NICE's methods
06 Nov 2020 Joint EU-UK pharmaceutical industry response to Specialised Committee outcome
25 Nov 2020 ABPI response to the Spending Review
27 Nov 2020 Disclosure UK: Further detail for 2019 published
30 Nov 2020 ABPI response to £20 million medicines manufacturing fund
02 Dec 2020 ABPI response to first COVID-19 vaccine approval